Outlook Therapeutics (OTLK) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Outlook Therapeutics faces the risk of delisting from the Nasdaq Capital Market if it fails to meet the minimum bid price requirement by April 15, 2024. The company’s stock has been trading below $1.00 for an extended period, prompting concerns about its ability to regain compliance. A delisting could severely impact the stock’s liquidity and the company’s access to capital markets, possibly triggering default under certain financial agreements. This situation may also erode investor confidence and diminish the company’s visibility among potential partners and stakeholders.
The average OTLK stock price target is $2.00, implying 372.70% upside potential.
To learn more about Outlook Therapeutics’ risk factors, click here.
